CD8A and neoplasm: Lastly, intratumoral injection of an mRNA encoding a fusion protein consisting of IFNβ and the ectodomain of transforming growth factor-β receptor II enhanced DC activation of CD8+ T cells in vitro and promoted rejection of the TC-1 tumor cell line in vivo (255).